Half Year Results 2025-26

RNS Number : 4590J

Beximco Pharmaceuticals PLC

24 June 2026

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

BEXIMCO PHARMACEUTICALS PLC.

Half Year Results 2025-26

Beximco Pharmaceuticals PLC. ("Beximco Pharma" or "the Company"; AIM Symbol: BXP, LEI No.:213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients today announces its unaudited financial results for the six months ended 31 December 2025.

Financial Highlights (Consolidated)

Half-year ended 31 December 2025

· Net revenue increased 15.8% to Bangladesh Taka ("BDT") 27,800.2m / £170.2m (2024-25: BDT 24,013.4m / £161.5m)

o Domestic sales increased 15.6% to BDT 25,743.1m / £157.6m (2024-25: BDT 22,262.3m / £149.2m)

o Export sales increased 17.5% to BDT 2,057.1m / £12.6m (2024-25: BDT 1,751.1m / £11.8m)

· Profit after tax increased 35.6% to BDT 4,794.2m / £29.3m (2024-25: BDT 3,535.0m / £23.8m)

Second quarter ended 31 December 2025

· Net sales increased 13.9% to BDT 14,005.3m / £85.7m (2024-25: BDT 12,299.6m / £82.7m)

· Profit after tax increased 29.8% to BDT 2,392.9m / £14.6m (2024-25: BDT 1,843.1m / £12.4m)

The detailed accounts can be viewed at the Company website: www.beximcopharma.com

For a summary of financial and operational highlights for the period from 1 January 2025 to 31 March 2026, please refer to the previous announcement titled: "Financial Results for the Periods from 1 January 2025 to 31 March 2026", released today.

(Exchange rates of £1=Taka 163.3559 for 31 December 2025 and £1=Taka 148.6917 for 31 December 2024 have been used in this announcement.)

For further information please visit www.beximcopharma.com or enquire to:

Beximco Pharma

S M Rabbur Reza, Chief Operating Officer

Tel: +880 2 58611001, Ext. 20111

Mohammad Ali Nawaz, Chief Financial Officer

Tel: +880 2 58611001, Ext. 20030

Mohammad Asad Ullah, FCS

Executive Director & Company Secretary

Tel: +880 2 41060531, Ext. 10140

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott

Tel: +44 (0)20 3368 3551 / 3555

SP Angel Corporate Finance LLP (Broker)

Matthew Johnson

Tel: +44 (0) 20 3470 0470

FTI Consulting

Simon Conway / Sam Purewal / Lucy Molloy

Tel: +44 (0)20 3727 1000

Notes to Editors

About Beximco Pharmaceuticals PLC.

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6,000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.

Beximco Pharmaceuticals PLC. and its Subsidiaries

Consolidated statement of financial position (Un-audited)

As at December 31, 2025

	December 31, 2025	Taka '000 June 30, 2025
ASSETS

Non-current assets	50,892,706	49,461,242
Property, plant and equipment	45,045,176	43,541,872
Right-of-use assets	443,240	485,613
Intangible assets	4,679,308	4,694,134
Deferred tax asset	29,438	44,079
Goodwill	674,570	674,570
Other investments	20,974	20,974

Current assets	28,181,095	23,786,005
Inventories	14,870,316	13,586,476
Spares and supplies	872,527	799,644
Trade and other receivables	3,898,541	3,628,788
Loans, advances, deposits and prepayments	3,521,274	2,814,492
Advance income tax	394,619	356,508
Short term investment	1,100,000	900,000
Cash and cash equivalents	3,523,818	1,700,097

TOTAL ASSETS	79,073,801	73,247,247

EQUITY AND LIABILITIES
Equity attributable to the owners of the company	57,828,336	53,107,137
Share capital	4,461,121	4,461,121
Share premium	5,269,475	5,269,475
Excess of issue price over face value of GDRs	1,689,637	1,689,637
Capital reserve on merger	294,951	294,951
Revaluation surplus	1,132,345	1,133,870
Unrealized gain/(loss)	18,149	18,149
Retained earnings	44,962,658	40,239,934

Non-controlling interest	4,021,863	3,977,499

TOTAL EQUITY	61,850,199	57,084,636

Non-current liabilities	8,469,200	7,769,471
Long term borrowings-net of current maturity	1,675,762	1,503,595
Liability for gratuity, pension and WPPF	4,216,553	3,690,096
Deferred tax liability	2,576,885	2,575,780

Current liabilities	8,754,402	8,393,140
Short term borrowings	2,096,301	2,025,394
Long term borrowings-current maturity	1,035,958	1,436,752
Trade and other payables	2,837,744	2,925,994
Accrued expenses	1,466,954	1,174,096
Dividend payable	158,644	302,272
Income tax payable	1,158,801	528,632
TOTAL LIABILITIES	17,223,602	16,162,611
TOTAL EQUITY AND LIABILITIES	79,073,801	73,247,247

Beximco Pharmaceuticals PLC. and its Subsidiaries

Consolidated statement of profit or loss and other comprehensive income (Un-audited)

For the period July-December 2025

				Taka '000

	July- December 2025	July- December 2024	October- December 2025	October- December 2024

Net revenue	27,800,156	24,013,407	14,005,327	12,299,557
Cost of goods sold	(14,186,735)	(13,034,847)	(7,053,986)	(6,729,105)

Gross profit	13,613,421	10,978,560	6,951,341	5,570,452

Operating expenses	(7,050,034)	(5,890,916)	(3,681,700)	(3,045,916)
General and administrative expenses	(751,969)	(688,377)	(397,274)	(383,929)
Selling, marketing and distribution expenses	(6,298,065)	(5,202,539)	(3,284,426)	(2,661,987)
Profit from operations	6,563,387	5,087,644	3,269,641	2,524,536

Other income	373,045	226,555	203,650	206,494
Finance cost	(373,548)	(487,978)	(187,238)	(209,534)
Profit before tax and WPPF	6,562,884	4,826,221	3,286,053	2,521,496
Contribution to WPPF	(318,210)	(235,259)	(161,054)	(124,419)
Profit before tax	6,244,674	4,590,962	3,124,999	2,397,077
Income tax expenses	(1,450,471)	(1,055,951)	(732,057)	(553,948)
Current tax	(1,434,282)	(1,063,402)	(731,713)	(563,273)
Deferred tax	(16,189)	7,451	(344)	9,325
Profit after tax	4,794,203	3,535,011	2,392,942	1,843,129

Profit/(loss) attributable to:
Owners of the Company	4,720,756	3,510,382	2,357,657	1,829,812
Non-controlling interest	73,447	24,629	35,285	13,317
	4,794,203	3,535,011	2,392,942	1,843,129
Other comprehensive income/(loss)	-	1	-	1
Total comprehensive income	4,794,203	3,535,012	2,392,942	1,843,130

Total comprehensive income attributable to:
Owners of the Company	4,720,756	3,510,383	2,357,657	1,829,813
Non-controlling interest	73,447	24,629	35,285	13,317
	4,794,203	3,535,012	2,392,942	1,843,130

Earnings per share (EPS)	10.58	7.87	5.28	4.10

Beximco Pharmaceuticals PLC. and its Subsidiaries

Consolidated statement of changes in equity (Un-audited)

For the period July-December 2025

For the period ended December 2025

										Taka '000
	Share capital	Share premium	Excess of issue price over face value of GDRs	Capital reserve on merger	Revaluation surplus	Unrealized gain/(loss)	Retained earnings	Equity attributable to owners of the company	Non-controlling interest	Total equity
Balance as on July 01, 2025	4,461,121	5,269,475	1,689,637	294,951	1,133,870	18,149	40,239,934	53,107,137	3,977,499	57,084,636
Total comprehensive income:
Profit/(loss) for the period	-	-	-	-	-	-	4,720,756	4,720,756	73,447	4,794,203
Other comprehensive income/(loss)	-	-	-	-	-	-	-	-	-	-
Transactions with the shareholders:
Cash dividend	-	-	-	-	-	-	-	-	(29,083)	(29,083)
Others:
Adjustment for depreciation on revalued assets	-	-	-	-	(1,968)	-	1,968	-	-	-
Adjustment for deferred tax on revalued assets	-	-	-	-	443	-	-	443	-	443
Balance as on December 31, 2025	4,461,121	5,269,475	1,689,637	294,951	1,132,345	18,149	44,962,658	57,828,336	4,021,863	61,850,199
Net asset value (NAV) per share							Tk.	129.63

For the period ended December 2024
	Share capital	Share premium	Excess of issue price over face value of GDRs	Capital reserve on merger	Revaluation surplus	Unrealized gain/(loss)	Retained earnings	Equity attributable to owners of the company	Non-controlling interest	Total equity
Balance as on July 01, 2024	4,461,121	5,269,475	1,689,637	294,951	1,137,306	18,148	35,079,327	47,949,965	3,952,938	51,902,903
Total comprehensive income:
Profit/(loss) for the period	-	-	-	-	-	-	3,510,382	3,510,382	24,629	3,535,011
Other comprehensive income/(loss)						1		1		1
Transactions with the shareholders:
Cash dividend							(1,784,448)	(1,784,448)	(25,003)	(1,809,451)
Others:
Adjustment for depreciation on revalued assets	-	-	-	-	(2,216)	-	2,216	-	-	-
Adjustment for deferred tax on revalued assets	-	-	-	-	499	-	-	499	-	499
Balance as on December 31, 2024	4,461,121	5,269,475	1,689,637	294,951	1,135,589	18,149	36,807,477	49,676,399	3,952,564	53,628,963
Net asset value (NAV) per share							Tk.	111.35

Beximco Pharmaceuticals PLC. and its Subsidiaries

Consolidated statement of cash flows (Un-audited)

For the period July-December 2025

	July-December 2025	Taka '000 July-December 2024
Cash flows from operating activities

Cash receipts from customers and others	27,795,936	23,931,261
Cash paid to suppliers and employees	(21,722,349)	(20,028,241)
Cash generated from operations	6,073,587	3,903,020

Interest paid	(370,767)	(492,268)
Interest received	118,107	18,480
Income tax paid	(842,226)	(694,481)
Net cash generated from operating activities	4,978,701	2,734,751

Cash flows from investing activities
Acquisition of property, plant and equipment	(2,463,593)	(1,526,647)
Intangible assets	(187,838)	(128,999)
Disposal of property, plant and equipment	13,844	21,849
Disposal of intangible assets	10,724	-
Short term investment	(200,000)	(500,000)
Net cash used in investing activities	(2,826,863)	(2,133,797)

Cash flows from financing activities

Net increase/(decrease) in long term borrowings	(228,192)	137,852
Net increase/(decrease) in short term borrowings	70,908	63,732
Dividend paid	(172,711)	(1,337)
Net cash from/(used in) financing activities	(329,995)	200,247
Increase/(decrease) in cash and cash equivalents	1,821,843	801,201
Opening cash and cash equivalents	1,700,097	854,106
Effect of exchange rate changes on cash and cash equivalents	1,878	(35)
Closing cash and cash equivalents	3,523,818	1,655,272

Net operating cash flows per share	11.16	6.13

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IR FJMFTMTJTBAF

Date	24 Jun 2026
Time	07:03:00
Category	Results
ID	4590J

Date	24 Jun 2026
Time	07:03:00
Category	Results
ID	4590J

t

Company Information

AI Summary

RNS Metadata

Company Information

AI Summary

RNS Metadata

Half Year Results 2025-26